News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
733,619 Results
Type
Article (44868)
Company Profile (312)
Press Release (688438)
Multimedia
Podcasts (108)
Webinars (16)
Section
Business (212619)
Career Advice (2191)
Deals (37173)
Drug Delivery (116)
Drug Development (84528)
Employer Resources (177)
FDA (16829)
Job Trends (15640)
News (360782)
Policy (34623)
Tag
Academia (2642)
Accelerated approval (11)
Adcomms (29)
Allergies (102)
Alliances (52251)
ALS (115)
Alzheimer's disease (1482)
Antibody-drug conjugate (ADC) (179)
Approvals (16809)
Artificial intelligence (341)
Autoimmune disease (34)
Automation (19)
Bankruptcy (379)
Best Places to Work (11853)
BIOSECURE Act (21)
Biosimilars (135)
Biotechnology (194)
Bladder cancer (95)
Brain cancer (38)
Breast cancer (376)
Cancer (3001)
Cardiovascular disease (234)
Career advice (1829)
Career pathing (33)
CAR-T (194)
CDC (34)
Cell therapy (522)
Cervical cancer (22)
Clinical research (69543)
Collaboration (1073)
Company closure (3)
Compensation (710)
Complete response letters (32)
COVID-19 (2723)
CRISPR (65)
C-suite (342)
Cystic fibrosis (117)
Data (3056)
Decentralized trials (2)
Denatured (33)
Depression (67)
Diabetes (362)
Diagnostics (6548)
Digital health (23)
Diversity (10)
Diversity, equity & inclusion (46)
Drug discovery (147)
Drug pricing (146)
Drug shortages (34)
Duchenne muscular dystrophy (133)
Earnings (89670)
Editorial (45)
Employer branding (21)
Employer resources (154)
Events (118014)
Executive appointments (876)
FDA (18529)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (963)
Gene editing (143)
Generative AI (28)
Gene therapy (402)
GLP-1 (880)
Government (4730)
Grass and pollen (5)
Guidances (182)
Healthcare (19195)
HIV (41)
Huntington's disease (31)
IgA nephropathy (43)
Immunology and inflammation (169)
Immuno-oncology (11)
Indications (40)
Infectious disease (2907)
Inflammatory bowel disease (155)
Inflation Reduction Act (10)
Influenza (62)
Intellectual property (122)
Interviews (342)
IPO (17044)
IRA (53)
Job creations (4180)
Job search strategy (1560)
Kidney cancer (14)
Labor market (53)
Layoffs (545)
Leadership (25)
Legal (8592)
Liver cancer (81)
Longevity (12)
Lung cancer (431)
Lymphoma (213)
Machine learning (11)
Management (61)
Manufacturing (422)
MASH (96)
Medical device (13614)
Medtech (13619)
Mergers & acquisitions (20856)
Metabolic disorders (927)
Multiple sclerosis (102)
NASH (20)
Neurodegenerative disease (129)
Neuropsychiatric disorders (38)
Neuroscience (2202)
NextGen: Class of 2025 (6739)
Non-profit (4569)
Now hiring (48)
Obesity (480)
Opinion (264)
Ovarian cancer (103)
Pain (121)
Pancreatic cancer (122)
Parkinson's disease (194)
Partnered (22)
Patents (315)
Patient recruitment (172)
Peanut (54)
People (60259)
Pharmaceutical (98)
Pharmacy benefit managers (25)
Phase I (21663)
Phase II (30551)
Phase III (22873)
Pipeline (1686)
Policy (230)
Postmarket research (2698)
Preclinical (9177)
Press Release (68)
Prostate cancer (146)
Psychedelics (39)
Radiopharmaceuticals (264)
Rare diseases (498)
Real estate (6382)
Recruiting (68)
Regulatory (23924)
Reports (50)
Research institute (2407)
Resumes & cover letters (372)
Rett syndrome (9)
RNA editing (9)
RSV (56)
Schizophrenia (96)
Series A (163)
Series B (112)
Service/supplier (14)
Sickle cell disease (64)
Special edition (21)
Spinal muscular atrophy (154)
Sponsored (33)
Startups (3811)
State (2)
Stomach cancer (16)
Supply chain (82)
Tariffs (66)
The Weekly (73)
Vaccines (821)
Venture capital (55)
Weight loss (315)
Women's health (48)
Worklife (17)
Date
Today (86)
Last 7 days (357)
Last 30 days (1855)
Last 365 days (32055)
2025 (17420)
2024 (36188)
2023 (40967)
2022 (52147)
2021 (56703)
2020 (55139)
2019 (47872)
2018 (36190)
2017 (33607)
2016 (33231)
2015 (39088)
2014 (33052)
2013 (28153)
2012 (30208)
2011 (30908)
2010 (28935)
Location
Africa (813)
Alabama (62)
Alaska (7)
Arizona (253)
Arkansas (14)
Asia (42237)
Australia (6700)
California (7531)
Canada (2392)
China (710)
Colorado (325)
Connecticut (322)
Delaware (197)
Europe (90584)
Florida (1145)
Georgia (248)
Hawaii (1)
Idaho (59)
Illinois (660)
India (28)
Indiana (376)
Iowa (17)
Japan (238)
Kansas (109)
Kentucky (29)
Louisiana (14)
Maine (64)
Maryland (1051)
Massachusetts (5643)
Michigan (248)
Minnesota (457)
Mississippi (3)
Missouri (91)
Montana (28)
Nebraska (25)
Nevada (82)
New Hampshire (66)
New Jersey (2122)
New Mexico (31)
New York (2113)
North Carolina (1141)
North Dakota (8)
Northern California (3302)
Ohio (240)
Oklahoma (16)
Oregon (40)
Pennsylvania (1630)
Puerto Rico (18)
Rhode Island (36)
South America (1188)
South Carolina (35)
South Dakota (1)
Southern California (2816)
Tennessee (127)
Texas (1145)
United States (28116)
Utah (224)
Virginia (200)
Washington D.C. (73)
Washington State (646)
West Virginia (4)
Wisconsin (69)
733,619 Results for "ns pharma inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
NS Pharma Announces Strategic Alliance with Boston Children’s Hospital to Develop New Therapies for Rare Diseases
July 2, 2025
·
1 min read
Drug Development
NS Pharma Shares Preliminary Results of Viltolarsen (NS-065 / NCNP-01) Phase 3 Clinical Trial (RACER53 Study)
NS Pharma, Inc., a subsidiary of Nippon Shinyaku Co., Ltd., announced that it has received preliminary analysis results from the global Phase 3 clinical trial of NS-065/NCNP-01.
May 27, 2024
·
6 min read
Pharm Country
NS Pharma, Inc. Shares New VILTEPSO® (Viltolarsen) Data at the MDA Clinical & Scientific Conference 2024
NS Pharma, Inc. (NS Pharma) is excited to announce participation in the 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference in Orlando, Florida, March 3 – 6.
March 6, 2024
·
4 min read
Drug Development
NS Pharma’s DMD Candidate Viltespo Fails Confirmatory Phase III Trial
NS Pharma, a subsidiary of Nippon Shinyaku, announced Monday that its Duchenne muscular dystrophy candidate Viltepso failed a late-stage confirmatory trial, showing no significant motor function improvements over placebo.
May 28, 2024
·
2 min read
·
Tristan Manalac
Press Releases
NS Pharma Announces Change in Commercial Leadership
November 26, 2024
·
4 min read
Business
NS Pharma Announces Research Alliance with MiNA Therapeutics to Develop Therapies for Rare Diseases of the Central Nervous System
NS Pharma, Inc. (NS Pharma) announced that its parent company, Nippon Shinyaku Co., Ltd. (Nippon Shinyaku) – headquartered in Kyoto, Japan, entered into a joint research agreement with MiNA Therapeutics – headquartered in London, United Kingdom, to develop nucleic acid drugs for the potential treatment of intractable and rare diseases of the central nervous system.
April 4, 2024
·
2 min read
Press Releases
FDA Grants Orphan Drug Designation to NS-229 for the Treatment of Eosinophilic Granulomatosis with Polyangiitis
April 21, 2025
·
2 min read
Press Releases
NS Pharma’s Galactic53 Trial Data Is Published in Scientific Reports
October 16, 2024
·
5 min read
Pharm Country
NS Pharma Unveils Duchenne Heroes, a Program to Inspire and Amplify the Voices of People Living with Duchenne Muscular Dystrophy
NS Pharma, Inc. announced the launch of Duchenne Heroes a program created to raise awareness and champion the voices of people affected by Duchenne muscular dystrophy.
November 21, 2023
·
3 min read
Pharm Country
The European Commission Grants Orphan Drug Designation to NS-229 for the Treatment of Eosinophilic Granulomatosis with Polyangiitis
NS Pharma, Inc. (NS Pharma), a subsidiary of Nippon Shinyaku Co., Ltd, announced today that the European Commission (EC) has granted orphan drug designation to NS-229, which is being developed for the treatment of the rare disease eosinophilic granulomatosis with polyangiitis (EGPA).
January 22, 2024
·
1 min read
1 of 73,362
Next